VADIS Trial: Phase II Trial of Nelipeimut-S Peptide Vaccine in Women With DCIS of the Breast

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Dec 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nelipepimut-S (Primary) ; GM-CSF-transduced tumour cell vaccine; Sargramostim
Indications Carcinoma; Early breast cancer
Focus Pharmacodynamics
Acronyms VADIS

Most Recent Events

16 Nov 2023 Status changed from active, no longer recruiting to completed.
11 Dec 2020 Results presented at the 43rd Annual San Antonio Breast Cancer Symposium
11 Dec 2020 According to a Sellas Life Sciences Group media release, final data with up to 6 months follow-up were presented at the 2020 San Antonio Breast Cancer Symposium.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight